Advertisements
Feeds:
Posts
Comments

Archive for the ‘Intellectual Property’ Category


Selection Process for Chief Innovation and Entrepreneurship Officer (CIEO) @Berkeley: Ecosystem Evangelist, Professor Richard Lyons, Berkeley’s ex-Dean of the Haas School of Business

 

Reporter: Aviva Lev-Ari, PhD, RN, Berkeley PhD’83

 

for @Berkeley Alumna Ecosystem Evangelist see

https://pharmaceuticalintelligence.com/2019-vista/executive-summary/

The University of California at Berkeley appointed professor Richard Lyons as the university’s first-ever chief innovation and entrepreneurship officer (CIEO).

The Selection Process

Professor Richard Lyons was selected for the CIEO position through a rigorous recruitment and selection process that attracted several hundred top-notch applications from all over the world. Throughout the process, Lyons stood out as a true visionary, a strategic leader and an ecosystem evangelist who could understand and activate the untapped potential of Berkeley’s innovation and entrepreneurship landscape.

 

“If together we can improve the transformation of Berkeley’s prodigious intellectual product, across the whole campus, into greater societal benefit, then we will have achieved a great deal,” said Lyons, in a statement.

Image Source: Courtesy of University of California, Berkeley, Doe Library Building with the  Campanile Tower in the background

Professor Richard Lyons,  Accomplishments as Berkeley’s ex-Dean of the Haas School of Business

  • He helped launch the Management, Entrepreneurship, & Technology (M.E.T.) dual-degree program in partnership with the College of Engineering.
  • He also initiated the Biology + Business dual degree program with Molecular & Cell Biology and
  • He revitalized the Berkeley-Haas Entrepreneurship Program (BHEP).
  • He helped the campus to launch the Berkeley SkyDeck startup accelerator in 2012 and served on its Governing Board, did that in collaboration with leadership in the Office of Research and College of Engineering.

 

SOURCE

https://venturebeat-com.cdn.ampproject.org/c/s/venturebeat.com/2019/07/10/richard-lyons-will-be-uc-berkeleys-first-ever-chief-innovation-and-entrepreneurship-officer/amp/

Advertisements

Read Full Post »


In-House Development of an intellectual property value calculator (IP-V-Cal) for Valuation of INTANGIBLE products: Intellectual property (IP) assets of Digital Printed Products (DPP) – Online Journal(s), e-Books and a Corpus of Real Time generated eProceedings of the Top Biotech Global Conferences

Author: Aviva Lev-Ari, PhD, RN

1. All the points I made, below in my e-mail 4AM on 6/28/2019, see below – to match Intangible Assets in Document #2, 4/19/2019 in Inbox of each FIT member.

(after reading Rick’s article we received a link to and after reading the link that I provided in this e-mail)

2. We Need Amnon to enter into an Excel spread sheet as Column #1 all the Contributing Factors to valuation in that 4AM e-mail

3. Columns #2,#3,#4 will be Gail, Amnon, Rick (Business Team)

4. Columns #5,#6 will be Dr. Williams, Prof. Feldman (our Board)

5. Columns #7,#8 #9,#10 will be Dr. Pearlman, Dr. Dror Nir, Dr. Saha, Dr. Irina (Scientists Team)

7. Each Column dedicated to each of out 10 alive and well Active FIT

Will be split into two columns

6. Column #11 will be Aviva’s 

8. First column of each of the 10 FIT members will be filled by each by a number between 50 to 100, representing the subjectively perceived contributing weight of the Factor mentioned in Column 1: list of factors contributing to Venture’s valuation

9. Second column of each of the 10 FIT members will list the member’s subjective perspective on Ranking the Factors in Column #1

10. To Column #1: each Business Team member (mentioned in 3, above), needs to contribute FIVE new factors taken from your discussion on Valuation add them with your initials to Column #1

11. Aviva will bring DATA from Article Scoring System already populating a database designed to quantify the 

11.1 Valuation of the Journal

11.2 Valuation of the BioMed e-Series: each book, each series, all 16 volumes

11.3 Author’s factor in pricing 11.1 and 11.2

 

12. Valuation of 70 eProceedings 

(60 by Aviva; 10 by Dr. Williams)

needs to be tied to a growth factor in LPBI Group’s INFLUENCE on Twitter

12.1 @pharma_BI

12.2 @AVIVA1950

12.3 Gail’s Twitter account

12.4 Dr. Williams’ Twitter account

12.5 Dr. Asha’s Twitter account

12.6 Dr. Irina’s Twitter account

Factors of INFLUENCE:

– Growth in #Followers on Twitter 

– Ratio #Tweets/#Likes

– Cumulative # of Followers’ Followers

13. LinkedIn

I discovered new features and I wish to conduct a Skype training session with narrow messaging to FIT members

Please contribute your thoughts, while 

 

– Amnon is building this Excel

– Irina will be designing DropBox for this Excel that TEN FIT members need to add a number 50 to 100, Ranking the relative importance of each factor for Venture Valuation

GREAT initiative by Business Team to focus on valuation, thank you.

Thank you all FIT members, get ready yo add your subjective numbers into the Valuation Excel.

Amnon, please share with me in a Skype session the draft of this Excel, before we deplore this instrument, place it in Dropbox and announce the window of one week when we collect 2×10 data points on each of the Factors in Column #1, 

Board members and Scientists: you are welcome to contribute Factors in Valuation of the Venture in Column #1, the longer this column, the greater the granularity. 

We can then focus only on factors that scored above the Mean or any cut off point we will agree upon.

Thank you all – it is exciting to get the entire Team, developing a custom tailor methodology for DIGITAL printed products, NO OFF THE SHELF MODEL WILL FIT US. 

Current valuation models that do NOT APPLY to our venture include the following:

“Book to market value” 

– we got Intangibles, Column #1

– LPBI Group’s Tangibles are royalties for books sold. 

(all data was reviewed by Dr. Williams, for Section #13 in Document #2, for the period, 4/2012 to 4/19/2019)

“VC investment dilution models” 

– we kept 100% of ownership 

– our shareholders are 12 FIT members: 

— >>>>>> 10 are active members 

– (Scientist Team: Formula in place) (Gail included)

– (Business Team: 10% of UPSIDE) (Gail included)

— >>>>>> Past commitments outstanding:

– to Dr. Larry and 

– to Adam Sonnenberg

– (Formula in place). 

– No UPSIDE, due to idle status since 2/6/2019, Exit period launch.

Thank you again.

Aviva Lev-Ari, PhD, RN

Editor-in-Chief, BioMed e-Series

http://PharmaceuticalIntelligence.com

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

On Jun 28, 2019, at 3:57 AM, Amnon Danzig <amnon.danzig@gmail.com> wrote:

This is a nice article that put in place Corporate Finance practices.

However, The Business Team currently is struggling in much more earlier stages of the valuation of the Group.

We have a long way to go before we are entering the valuation scene in numeric terms.

Aviva,

I must confess that in the last two weeks we (Rick, Gail and me) invested huge amount of work to disclose the real valuation of the Group.

It is a work-in-process.

Thank you for your patience.

Amnon

Amnon Danzig

Business Strategy 

https://lnkd.in/e-zTVz4

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Israel

http://pharmaceuticalintelligence.com 

e-Mailamnon.danzig@gmail.com

(M) +972-54-6998405

 www.amnondanzig.com

SkypeID: Amnon.Danzig  LinkedIn Profile Twitter Profile

On Fri, Jun 28, 2019 at 10:30 AM Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

What is Aviva’s take on LPBI Group Valuation?

https://bothsidesofthetable.com/do-you-really-even-need-vc-72013e985fab

  • Advantages of LPBI Group:
  1. We had low barrier to entry and 
  2. We had/have Zero labor cost
  3. We are virtual, therefore, no overhead expenses 
  4. Run rate at WordPress.com Business Premium Annual Fee $200 and LinkedIn Annual Business Premium $1000
  5. Our 1st CARDINAL factor of production [The Team] is the DEAPTH and very diverse EXPERTISE residing in the Scientist Team and in the Business TEAM
  6. Leadership expressed by new timely challenge selection – Directions into new domains
  7. Team ability to swarm around new domains (new timely challenge selection), Examples: 
  • 2015-2016 – 3D BioPrinting – Book: Series E, Volume 4
  • Volume 4: Medical 3D BioPrinting – The Revolution in Medicine, Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices. On Amazon.com since since 12/30/2017

https://www.amazon.com/dp/B078QVDV2W

  • 2016-2017 – Drug Discovery – JV with SBH Sciences, Dr. Raphael Nir

https://pharmaceuticalintelligence.com/drugdiscovery-lpbi-group/

  • 2019-2020 – AI + ML in Medicine – Book: Series B, Volume 2

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

  1. Our 2nd CARDINAL factor of Leadership is the FIDELITY of a CORE team of Scientists
  2. Aviva’s ability to multitask on several levels – FIVE persons in just One woman (nee: 1950): 
  • LPBI Group’s DAILY activity on Twitter, LinkedIn, Facebook
  • IN PERSON at +60 Conferences – yielded a Corpus of eProceedings N=70 [10 by Dr. Williams 
  • Curator of new content – Journal is LIVE at 

1,639,029 eReaders 

Content

5,642

Posts

686

Categories

10,083

Tags

  • Book Editor – multiple domains of knowledge: Series A, B, D, E
  • Full functions of Editor-in-Chief: 16 Titles, content acquisition, eTOCs designer
  • Relations builder with multiple Ecosystems: Israel, US, Europe – stay tune

4/19/2019 

@pharma_Bi # Followers = 505 

6/28/2019

@pharma_Bi # Followers = 519 RatioTweets to Likes: 25,000/3,086

4/19/2019 

@AVIVA1950 # Followers = 359

6/28/2019

@AVIVA1950 # Followers = 439 RatioTweets to Likes: 11,000/5,615

How can you use all of the above for your Valuation Modeling???

Read Full Post »


Pfizer buys out Array BioPharma for $11.4 Billion to beef up its oncology offerings

Reporter: Stephen J. Williams, PhD

As reported in FiercePharma.com:

by Angus Liu |

Three years after purchasing Medivation for $14.3 billion, Pfizer is back with another hefty M&A deal. And once again, it’s betting on oncology.

In the first big M&A deal under new CEO Albert Bourla, Pfizer has agreed to buy oncology specialist Array BioPharma for a total value of about $11.4 billion, the two companies unveiled Monday. The $48-per-share offer represents a premium of about 62% to Array stock’s closing price on Friday.

With the acquisition, Pfizer will beef up its oncology offerings with two marketed drugs, MEK inhibitor Mektovi and BRAF inhibitor Braftovi, which are approved as a combo treatment for melanoma and recently turned up positive results in colon cancer.

The buy will enhance the Pfizer innovative drug business’ “long-term growth trajectory,” Bourla said in a Monday statement, dubbing Mektovi-Braftovi “a potentially industry-leading franchise for colorectal cancer.”

RELATED: Array’s ‘extremely compelling’ new colon cancer data spark blockbuster talk

In a recent interim analysis of a trial in BRAF-mutant metastatic colorectal cancer, the pair, used in tandem with Eli Lilly and Merck KGaA’s Erbitux, produced a benefit in 26% of patients, versus the 2% that chemotherapy helped. The combo also showed it could reduce the risk of death by 48%. SVB Leerink analysts at that time called the data “extremely compelling.”

Right now, one in every three new patients with mutated metastatic melanoma is getting the combo, despite its third-to-market behind combos from Roche and Novartis, Andy Schmeltz, Pfizer’s oncology global president, said during an investor briefing on Monday.

It is being studied in more than 30 clinical studies across several solid tumor indications. Moving forward, Pfizer believes the combo could potentially be used in the adjuvant setting to prevent tumor recurrence after surgery, Pfizer’s chief scientific officer, Mikael Dolsten, said on the call. The company is also keen to know how it could be paired up with Pfizer’s own investigational PD-1, he said, as the combo is already in studies with other PD-1/L1s.

But as Pfizer execs have previously said, the company’s current business development strategy no longer centers on adding revenues “now or soon,” but rather on strengthening Pfizer’s pipeline with earlier-stage assets. And Array can help there, too.

“We are very excited by Array’s impressive track record of successfully discovering and developing innovative small-molecules and targeted cancer therapies,” Dolsten said in a statement.

On top of Mektovi and Braftovi, Array has a long list of out-licensed drugs that could generate big royalties over time. For example, Vitrakvi, the first drug to get an initial FDA approval in tumors with a particular molecular feature regardless of their location, was initially licensed to Loxo Oncology—which was itself snapped up by Eli Lilly for $8 billion—but was taken over by pipeline-hungry Bayer. There are other drugs licensed to the likes of AstraZeneca, Roche, Celgene, Ono Pharmaceutical and Seattle Genetics, among others.

Those drugs are also a manifestation of Array’s strong research capabilities. To keep those Array scientists doing what they do best, Pfizer is keeping a 100-person team in Colorado as a standalone research unit alongside Pfizer’s existing hubs, Schmeltz said.

Pfizer is counting on Array to augment its leadership in breast cancer, an area championed by Ibrance, and prostate cancer, the pharma giant markets Astellas-partnered Xtandi. For 2018, revenues from the Pfizer oncology portfolio jumped to $7.20 billion—up from $6.06 billion in 2017—mainly thanks to those two drugs.

Source: https://www.fiercepharma.com/pharma/pfizer-never-say-never-m-a-buys-oncology-innovator-array-for-11-4b

 

About Array BioPharma

Array markets BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib)  tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K  mutation in the United States and with partners in other major worldwide markets.* Array’s lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. Array’s pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Eli Lilly), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi® (larotrectinib, partnered with Bayer AG) is approved in the United States and Ganovo® (danoprevir, partnered with Roche) is approved in China.

 

Other Articles of Note of Pfizer Merger and Acquisition deals on this Open Access Journal Include:

From Thalidomide to Revlimid: Celgene to Bristol Myers to possibly Pfizer; A Curation of Deals, Discovery and the State of Pharma

Pfizer Near Allergan Buyout Deal But Will Fed Allow It?

Pfizer offers legal guarantees over AstraZeneca bid

Re-Creation of the Big Pharma Model via Transformational Deals for Accelerating Innovations: Licensing vs In-house inventions

Read Full Post »


Real Time Coverage @BIOConvention #BIO2019: Keynote Address Jamie Dimon CEO @jpmorgan June 5 Philadelphia

Reporter: Stephen J. Williams, PhD @StephenJWillia2

 

  • Dr Janet Woodcock from FDA was given the BIO Heritage award for leading the FDA from safety focus of 90s to the Voice of the Patient. She became a champion for advocacy groups
  • Governor Phil Murphy, Governor of New Jersey, received the Governor of the Year Award.  New Jersey known as medicine chest of the world, have first 3D printed drug on market and number two in biotech and number one on drug approvals.  We must do more to foster stem education.  It will take private and public capital investment.  New Jersey matches federal dollars and had doubled the angel investor tax credit.
  • Dr. Kakkis CEO of Ultragenix wins the Genzyme Henri Termeer Award for visionary work.  Dr. Termeer recently passed.  Dr. Kakkis is awarded for work with patients of rare diseases and help formulating legislation to help patients with rare disease have access to investigational drugs quickly.
  • Dr. Jeremy Levin from OVID named new chair of BIO

Interview with Jamie Dimon, CEO of JPMorgan

  • Mr Dimon had recently survived throat cancer and now has a renewed dedication to improving people’s lives.  With Amazon had embarked on a nonprofit experimental model to streamline healthcare for their employees.  He said the hardest part of going through cancer was telling his parents and children.
  • On the bailout he said it was a lie all banks needed TARP but could not just give to some and not all.  He says the financial system in US is very solid so next downturn will not come from financial sector and never is from geopolitical but trade issues could be a catalyst. Policy usually always does the opposite of what is intended.  He announced no intention of running for President of US.
  • We need to keep a growth agenda which includes education and infrastructure, without these competitive business tax relief does no account for much.  We need a better conversation of how government handles finances
  • Immigration, education very important.  Higher education needs to reduce costs and incentivize the people they bring in to stay here.
  • on healthcare:  JPM had reduced the deductables to zero for workers making $60,000 or less

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Other Article on this Open Access Journal on Global Partnerships, Global Investing and JPMorgan Include:

 

Read Full Post »


Proprietary IP Asset Sale Opportunity of SeraSeal® Global Rights Purchase with the CE License

Guest Author: Dr. Jukka Karjalainen, MD, PhD

 

IP Asset Sale Opportunity by Dr. Jukka Karjalainen, IP and Asset Agent to Leon Wortham Owner of IP and CEO of Wortham Laboratories, Tennessee, USA including the intellectual property of SeraSeal® with the CE license.

The value proposition of purchase of IP of SeraSeal® is available for global rights purchase. The proprietary IP of SeraSeal® is protected from replication and has no lifetime limits.

 

 

Dr. Jukka Karjalainen, MD, PhD

SeraSeal Intellectual Property Agent

Pharma Consulting Services (PCS) Inc.

Toronto, Ontario, Canada

Cell: + 1 (416) 258 4495

Email: jukan_koti@hotmail.com

 

TO SENIOR BUSINESS EXECUTIVE, CEO, President , CBO, CMO, CTO, CSO PRESENTING THE OPPORTUNITY:

SeraSeal®

A PRIMARY HEMOSTATIC AGENT CAPABLE OF:

  • control all forms of bleeding quickly without destroying tissue
  • to use immediately without any preparation time
  • get the product to any part of body, even to closed systems with multiple delivery systems
  • be extremely effective in the presence of anticoagulant drugs and coagulopathies (bleeding disorders)

Problem and Challenge

All of the hemostatic agents on the market are adjunct or secondary products, which are added after the bleeding is controlled and their use is limited to surgical procedures. This suboptimal treatment puts patients at risk of dying of injuries and surgical procedures.

All competitor hemostatic and tissue sealing products are only able to arrest bleed in minutes as compared to ONLY SECONDS with SeraSeal®.

Industry and Market Overview

The market size of global hemostasis and tissue sealing products was valued at $5.35 Billion (USD) in 2018. It is anticipated to expand at a CAGR of 8.7% annual rate during the 7-year forecast period. Out of the 15+ competitors, four companies dominate 98% of the total market: Baxter, J&J, Ethicon US, LLC., C. R. Bard, Inc., B. Braun Melsungen AG, Pfizer Inc., Z-Medica, LLC., CryoLife, Inc., Integra LifeSciences, Advanced Medical Solutions Group plc, GELITA AG.

The lucrative market growth over the next seven years is due to increase in demand from increasing surgery volumes, resulting from growth in geriatric population and prevalence of chronic conditions (Grand View Research: Hemostasis & Tissue Sealing Agents Market Size Report, 2019-2026).

The major competitors are the fibrin glues, which are a two-component hemostatic agent, delivered by a double barrel syringe, forming a physical barrier over the wound. This method of approach will stop venous bleeds in 1-3 minutes and capillary arteries in 5-10 minutes. SeraSeal®, however is a one component agent that interacts with the patient’s own blood, acting as a catalyst to form a clot in 1-2 seconds for most bleeds, and less than 60 seconds for large arterial hemorrhages, even in the presence of anticoagulant therapy or coagulation disorders.

The fibrin glues are primarily in the cardio-vascular market, with some applications in liver and gastro surgeries. SeraSeal® having many delivery systems and achieving hemostasis in seconds, can be applied to any part of the body, which opens a broad market. Unlike hemostatic agents on the market, SeraSeal® can be used in all surgical departments, hospital departments, emergency/trauma centers, medical and surgical clinics, private practice, dentistry, paramedics, veterinary medicine, military, law enforcement, and the consumer market in the form of first-aid products for the home, business, recreational and sporting events.

SeraSeal® is Ultimate and Only Solution

SeraSeal® is a the only CE licensed primary hemostatic agent registered in 47 countries as the first line of defense to arrest bleeding in in closed wounds, such as gunshots, stabbings, or impaled wounds, and open large gaping wounds, and surgical bleeding and used in military, by paramedics, emergency/trauma center personnel, and law enforcement for immediate stopping of venous or arterial bleedings, even in the presence of anticoagulant therapy drugs and in patients with bleeding disorders. Efficacy vs competitors are discussed in the Journal of Gastroenterology, July 2015, and Journal of Cranio-Maxillo-Facial Surgery, June 2016.

SeraSeal® is capable of reducing surgical time by 50%, eliminates blood transfusion by 90%, and reduces anesthetic and pain medication. Efforts to reduce health care costs are actively pursued worldwide by government health care agencies, private hospitals, medical and surgical clinics, and insurance companies. Other cost savings are available.

SeraSeal® can be delivered to any part of the body through multiple delivery systems.

–   Syringe for deep wounds and arterial bleeds: Used for treatment of the visceral organs, particularly the spleen. Also used for lacerations, incisions, dissections, biopsies, resections, and fiber optic and catheter delivery.

–   SeraSeal® Foam is designed to arrest bleeding in closed wounds, such as gunshot, stabbing, or impaled wounds, and open large gaping wounds. The Foam can be applied by a medic, a buddy in the field, or can be self-applied.

–   Spray, scope, trochar, catheter, trauma dressing, battlefield dressing, surgical sponges, dental compresses, swab, bandage strip.

–   Fiber optics, where SeraSeal® can be delivered semi-invasively through scopes, such as an endoscope for a bleeding ulcer.

–   All products are stable with long shelf lives, require no preparation, and are immediately applicable to the patient.

–   SeraSeal® does not create chemical burns, but rather, accelerates healing for the patient. By contrast, all competing products on the market are secondary hemostatic agents, effective only for minor bleeds requiring direct pressure, cauterization, and some are limited to external use only.

With SeraSeal® Hemostasis occurs in seconds:

–  Venous bleeds: 1-3 seconds / Small artery: 5-10 seconds / Medium artery: 15-30 seconds / Large artery:   <60 seconds

 

 

FOAM                                                 BANDAGE STRIPS                                                     HEMOSTATIC SEALAND

VIALS                                     BATTLEFIELD DRESSING                                                     SERASEAL® SWAB

 

How It Works

BANDAGE STRIPS

 

SERASEAL® SWAB

VIALS

FOAM


HEMOSTATIC SEALAND

 

 

BATTLEFIELD DRESSING

 

SeraSeal® is derived from proprietary bovine hemostatic factors and specifically formulated for its applications. It is the World’s ONLY Primary Hemostatic Agent, meaning that it stops major hemorrhages in seconds, even in the presence of anticoagulant therapy or factor deficiencies, without the need for ANY of the traditional applications of pressure, elevation, tourniquets or cauterization.

Current Market Position
Market position is shared with companies who are interested in asset purchase evaluation in detail and have signed an NDA.
IP Asset Sale Opportunity
Dr. Jukka Karjalainen, IP and Asset Agent to Leon Wortham Owner of IP and CEO of Wortham Laboratories, Tennessee, USA (http://worthamlabs.com/secure_landing ), presents herein an asset purchase opportunity to global pharmaceutical companies, including the intellectual property with the CE license.

The value proposition of purchase of IP of SeraSeal® is available for global rights purchase. The proprietary IP of SeraSeal® is protected from replication and has no lifetime limits.

 

To further discuss your interest to purchase the IP assets and certification transfer, please contact me

 

Jukka Karjalainen, MSc, MD, PhD, Docent, Professor

Board Certified in Pharmaceutical Medicine, Pediatrics, General Medicine, Immunology and Diabetes

CEO, President and Director, Pharma Consulting Services (PCS) Inc.

 

 

 

Email: jukan_koti@hotmail.com

Main:

+1 (416) 358-4495

 

SOURCE

On 5/27/19, 11:21 AM, “Jukka K” <jukan_koti@hotmail.com> wrote:

Attached.

Jukka

Read Full Post »


At California Central District Court Juno Therapeutics, Inc. et al v. Kite Pharma, Inc. – Multi-party Patent Infringement

Curator and Reporter: Aviva Lev-Ari, PhD, RN

 

Infringement of Patent: US7446190B2 – which is exclusively licensed to Juno Therapeutics, Inc.

United States

Inventor
Michel Sadelain
Renier Brentjens
John Maher
Current Assignee
Sloan-Kettering Institute for Cancer Research

Worldwide applications
2003  US

Application US10/448,256 events
2002-05-28
Priority to US38387202P
2008-11-04
Application granted
Application status is Active
Adjusted expiration
Show all events

 

SUMMARY OF INVENTION

The present invention provides chimeric TCR’s, nucleic acid polymer encoding the chimeric TCR’s and methods of using the chimeric TCR’s to facilitate T cell response to a specific target. The chimeric TCR’s of the invention combine, in a single chimeric species, the intracellular domain of CD3 ζ-chain (“zeta chain portion”), a signaling region from a costimulatory protein such as CD28 and a binding element that specifically interacts with a selected target. Thus, in accordance with a first aspect of the invention, there is provided a nucleic acid encoding a chimeric T cell receptor, said chimeric T cell receptor comprising a zeta chain, a CD28 signaling region and a binding element that specifically interacts with a selected target. In accordance with a second aspect of the invention, there is provided a chimeric T cell receptor comprising a zeta chain portion, a CD28 signaling region and a binding element.

In accordance with the method of the invention a chimeric TCR is provided which comprises a zeta chain portion, a co-stimulatory signaling element and a binding element which specifically interacts with a cellular marker associated with target cells. T-lymphocytes from the individual to be treated, for example a human individual, are transduced with the chimeric TCR. This transduction may occur ex vivo, after which the transduced cells are reintroduced into the individual. As a result, T cell immune response is stimulated in the individual to the target cells.

SOURCE

https://patents.google.com/patent/US7446190B2/en

  • Prior Art Search results: (cells) (nucleic acid) (acid polymer) (cell) (cd28) before:priority:2002-05-28

Assignees Inventors include:

C12P21
C12P21/00
C12P
C12P21/02
C07K14/52
C07K14/715
C07K14/54
C07K14/521
C07K14/47
C07K14/46
C12N9/6432
C12Y304/21006
C07K14/47
C07K14/46
C07K14/475
C07K14/435
A01K2217
A01K2217/00
A01K
A01K2217/075
C12N2533/00
C12N2533/14
C12N2533/18
C12N2533/30
G01N33/502
G01N33/5041
Y10S435/973
G01N33/5008
B01J2219/00648
B01J2219/00306
B82Y15/00
B01J2219/00646
C07K14/70532
C07K14/70503
C07K16/2827
A61K2039/5158
A61K38/1774
A61K31/33
A61K45
A61K45/06
C07K14/70532
C12N2795
C12N2795/00
C12N2795/00011
C07K14/47
C07K14/46
A61K48/00
C07K14/435
C12N2510/00
C12N2502/99
C12N2501/515
C12N2501/51
C07K14/70503
A61K38/00
A61K
C07K14/705
G01N33/6878
G01N33/68
C07K1/047
C07K1/04
C07K14/70503
A01K2217/05
C07K14/705
A01K2217
Y02A50/38
A61K2039/6068
A61K2039/6025
C07K2319/21
C07K14/47
C07K14/46
A61K48/00
C07K14/435
C07K14/4747
C07K14/70575
A61K45/06
A61K45

SOURCE

https://patents.google.com/?q=cells&q=nucleic+acid&q=acid+polymer&q=cell&q=cd28&before=priority:20020528&scholar

 

IRELL & MANELLA LLP Morgan Chu (SBN 70446) Alan J. Heinrich (SBN 212782) Elizabeth C. Tuan (SBN 295020) 1800 Avenue of the Stars, Suite 900 Los Angeles, California 90067-4276 Telephone: (310) 277-1010 Facsimile: (310) 203-7199 Attorneys for

Plaintiffs JUNO THERAPEUTICS, INC., MEMORIAL SLOAN KETTERING CANCER CENTER, and SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF CALIFORNIA Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, and Sloan Kettering Institute for Cancer Research,,

Plaintiffs, v. Kite Pharma, Inc., Defendant. ) ) ) ) ) ) ) ) ) ) ) )

CASE NO.: 2:17-CV-07639

COMPLAINT FOR PATENT INFRINGEMENT

DEMAND FOR JURY TRIAL

Case 2:17-cv-07639 Document 1 Filed 10/18/17 Page 1 of 14 Page ID #:1

Knowing that it infringes the ’190 Patent, Kite challenged the validity of all claims of the ’190 Patent in an inter partes review (“IPR”) in the United States Patent and Trademark Office (“PTO” or “Office”) before the Patent Trial and Appeal Board (“PTAB” or “Board”). The PTAB instituted the IPR and then upheld all claims of the ’190 Patent in a Final Written Decision issued December 16, 2016. The PTAB concluded that Kite did not even show “by a preponderance of the evidence”—the lower standard applicable to validity challenges in an IPR—that any claim of the ’190 Patent was unpatentable.

Kite recently received marketing approval from the Food and Drug Administration (“FDA”) for its Yescarta™ product (axicabtagene ciloleucel) (“axicel” or “Yescarta,” also known as “KTE-C19”) on October 18, 2017. Plaintiffs accordingly bring suit against Kite for infringement based on Kite’s making, using, offering to sell, and selling of its chimeric antigen receptor products that comprise the claimed nucleic acid polymers of the ’190 Patent. 35 U.S.C. § 271(a). Plaintiffs hereby allege for their Complaint against Defendant Kite, on personal knowledge as to their own actions and on information and belief as to the actions of others,

26. Indeed, the DNA sequence of Kite’s retroviral vector demonstrates that Kite’s anti-CD19 chimeric TCR falls within the scope of the ’190 Patent claims. In a document Kite filed with the Recombinant DNA Advisory Committee (“RAC”), a federal committee that reviews clinical trial protocols that are either directly funded by the National Institutes of Health (“NIH”) or conducted at institutions that receive NIH funding, Kite provided the DNA sequence of KTE-C19’s anti-CD19 chimeric TCR vector. Exhibit 10 (KTE-C19 DNA Sequence). The RAC filing described the retroviral vector used as

encoding a chimeric antigen receptor directed against the B cell antigen, CD19 . . . The retroviral vector utilizes the MSGV1 (murine stem cell virus-based splice-gag vector 1) retroviral vector backbone and consists of 7026 bps including the 5’ long terminal repeat (LTR) from the murine stem cell virus (promoter), packaging signal including the splicing donor (SD) and splicing acceptor sites, FMC63- based (anti-CD19 FMC63-28) CAR protein containing a signal peptide (human GM-CSF receptor), FMC63 light chain variable region (FMC63 VL), linker peptide, FMC63 heavy chain variable region (FMC63 VH), CD28 (hinge, transmembrane and cytoplasmic region), and TCR-zeta (cytoplasmic region), followed by the murine stem cell virus 3’LTR. This particular vector was provided by Dr. Steven A. Rosenberg from the Surgery Branch/NCI and is the same vector used in an ongoing RAC-approved clinical trial of which Dr. Stephen A. Rosenberg is the Principal Investigator (OBA/RAC submission 0809-940). . . . [T]he complete nucleotide sequence as determined by the standard nucleotide sequencing protocol is shown in Appendix 2 of this application.

27. During the IPR Kite initiated against the ’190 Patent, Sloan Kettering’s expert, Prof. Thomas Brocker, the Director of the Institute for Immunology at the Ludwig-Maximilians University in Munich, Germany, compared the chimeric TCR used by Kite’s scientific collaborators to the claims of the ’190 Patent, demonstrating that Kite’s collaborators’ chimeric TCR construct, and thus, Kite’s own KTE-C19 product, falls within the scope of at least claims 1-3 and 5 of the ’190 Patent. Exhibit 12 (Brocker Declaration), ¶ 224. The NCI chimeric TCR analyzed by Prof. Brocker contains the same nucleotide sequence as KTE-C19’s chimeric TCR. See Exhibit 11 (RAC Filing).

28. On October 18, 2017, Kite received approval for the FDA to market and sell Yescarta (axicabtagene ciloleucel) in the United States.

COUNT 1:

INFRINGEMENT OF THE ’190 PATENT UNDER 35 U.S.C. § 271(a)

29. Plaintiffs re-allege and incorporate by reference the allegations contained in paragraphs 1-28 above.

30. to 40. are Plaintiffs’ description of Defendant Infringement on claims of the Patent

MAIN SOURCE for Filings by Plaintiffs

http://litigationtools.maxval-ip.com/UnifiedPatentViewDocument/home/index?caseid=128416

 

 

Plaintiffs:

  • Juno Therapeutics, Inc.,
  • Memorial Sloan Kettering Cancer Center,
  • Sloan Kettering Institute for Cancer Research

Defendant and Counterclaimant

  • Kite Pharma, Inc.

 

Effective April 17, 2018, Magistrate Judge Rozella A. Oliver will be located at the Edward R. Roybal Federal Building and U.S. Courthouse, COURTROOM 590 on the 5th floor, located at 255 East Temple Street, Los Angeles, California 90012. All Court appearances shall be made in Courtroom 590 of the Roybal Federal Building,

100

Oct 9, 2018

MINUTE IN CHAMBERS CLAIM CONSTRUCTION ORDER by Judge S. James Otero: The Court finds that a POSITA encountering the 190 Patent prior to the CoC would have understood SEQ ID NO:6 to begin with nucleotide 336 of the CD28 protein. The Court construes the disputed claim terms as follows: 1. The amino acid sequence encoded by SEQ ID NO:6 before the Certificate of Correction means Amino Acids 113-220 of CD28 (starting with lysine (K)) and after the Certificate of Correction means Amino Acids 114-220 of CD28 (starting with isoleucine (I)). 2. nucleic acid polymer encoding… a binding element that specifically interacts with a selected target is given its plain and ordinary meaning. (shb) (Entered: 10/10/2018)

 

Main Doc

 

Juno Therapeutics, Inc. et al v. Kite Pharma, Inc. (2:17-cv-07639), California Central District Court

California Central District Court
Judge: S James Otero
Referred: Jacqueline Chooljian
Case #: 2:17-cv-07639
Nature of Suit 830 Property Rights – Patent
Cause 35:271 Patent Infringement
Case Filed: Oct 18, 2017
Docket last updated: 03/08/2019 11:59 PM PST 

Thursday, March 07, 2019
150 order For Order Thu 12:50 PM 
ORDER GRANTING DEFENDANT KITE PHARMA, INC.S EX PARTE APPLICATION FOR AN EXTENSION OF TIME FOR THE MAGISTRATE JUDGE TO HEAR MOTIONS TO COMPEL PRODUCTION OF DOCUMENTS AND WITNESSES144 by Judge S. James Otero: 1. Time is extended until April 17, 2019, for the Magistrate Judge to hear (a) any motions to compel Plaintiffs to produce documents that Kite has already identified as deficient in Plaintiffs production and Plaintiffs have not yet produced, and (b) a motion to compel Bristol-Myers Squibb Company to produce documents in response to Kites subpoena; and 2. Time is extended until May 10, 2019, for the Magistrate Judge to hear a motion to compel deposition testimony regarding the documents described in paragraph 1 above. (lc) Modified on 3/7/2019 (lc)
Wednesday, March 06, 2019
149 transcript -Transcript Order Form (G-120) Wed 2:56 PM 
TRANSCRIPT ORDER as to Defendant Kite Pharma, Inc. for Court Smart (CS). Court will contact Adam R. Lawton at adam.lawton@mto.com with further instructions regarding this order. Transcript preparation will not begin until payment has been satisfied with the transcription company. (Lawton, Adam)
Tuesday, March 05, 2019
147 respm Reply (Motion related) Tue 5:31 PM 
REPLY in support of EX PARTE APPLICATION for Order for Extension of Time for the Magistrate Judge to Hear Motions to Compel Production of Documents and Witnesses 144 filed by Defendant Kite Pharma, Inc..(Lawton, Adam)
Att: 1 Reply Declaration of Adam R. Lawton
146 respm Objection/Opposition (Motion related) Tue 12:26 PM 
OPPOSITION Ex Parte Application re: EX PARTE APPLICATION for Order for Extension of Time for the Magistrate Judge to Hear Motions to Compel Production of Documents and Witnesses 144Opposition filed by Plaintiffs Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research.(Wells, Crawford)
Att: 1 Declaration,
Att: 2 Exhibit 1
Monday, March 04, 2019
148 minutes Telephone Conference For Order re Discovery Matter Wed 9:27 AM 
MINUTES OF CONTINUED PRE-MOTION TELEPHONIC DISCOVERY CONFERENCE settling139 Motion re: Informal Discovery Dispute held before Magistrate Judge Karen L. Stevenson. Should Judge Otero grant Kite’s Ex Parte Application, Kite may file a motion to compel. In the interim, at the request of counsel for non-party BMS, who does not receive the CM/ECF notifications in this case, the Court ORDERS Defendant Kite, to provide copies to BMS counsel of the following: (1) Minutes of Pre-Motion Telephonic Discovery Conference held on February 26, 2019, (Dkt. No. 138) (see document for further details). Court Recorder: XTR 03-04-19. (hr)
145 respm Declaration (Motion related) Mon 12:52 PM 
DECLARATION of Adam R. Lawton (Corrected) in support of EX PARTE APPLICATION for Order for Extension of Time for the Magistrate Judge to Hear Motions to Compel Production of Documents and Witnesses 144 filed by Defendant Kite Pharma, Inc.. (Lawton, Adam)
144 17 pgs motion Order Mon 11:50 AM 
EX PARTE APPLICATION for Order for Extension of Time for the Magistrate Judge to Hear Motions to Compel Production of Documents and Witnesses filed by Defendant Kite Pharma, Inc.. (Lawton, Adam)
Att: 1 Proposed Order,
Att: 2 Declaration of Adam R. Lawton,
Att: 3 Exhibit 1,
Att: 4 Exhibit 2,
Att: 5 Exhibit 3,
Att: 6 Exhibit 4,
Att: 7 Exhibit 5,
Att: 8 Exhibit 6,
Att: 9 Exhibit 7,
Att: 10 Exhibit 8,
Att: 11 Exhibit 9,
Att: 12 Exhibit 10,
Att: 13 Exhibit 11,
Att: 14 Exhibit 12,
Att: 15 Exhibit 13,
Att: 16 Exhibit 14,
Att: 17 Exhibit 15,
Att: 18 Exhibit 16
Thursday, February 28, 2019
143 order Leave to File Excess Pages Thu 10:50 AM 
ORDER GRANTING-IN-PART DEFENDANT KITE PHARMA, INC.’S APPLICATION FOR LEAVE TO FILE A 10-PAGE REPLY BRIEF IN SUPPORT OF MOTION FOR SUMMARY JUDGMENT OF NONINFRINGEMENT140 by Judge S. James Otero. It is hereby ordered that Defendant Kite Pharma, Inc. may file a reply brief of no more than 10 pages in support of its motion for summary judgment of noninfringement. Plaintiffs are permitted to file a sur-reply, not to exceed 7 pages, addressing the admissibility of the expert declarations submitted in support of its opposition to Defendant’s motion for summary judgment of noninfringement. The sur-reply shall be filed no later than 5 days from Defendant’s reply. IT IS SO ORDERED. (lom)

Juno Therapeutics, Inc. v. Kite Pharma, Inc. (2:17-cv-07639)

District Court, C.D. California

 

 

 

 

 

 

 

Recorded here ONLY if PDF is Downloadable

Oct 18, 2017

COMPLAINT Receipt No: 0973-20685642 – Fee: $400, filed by Plaintiffs Juno Therapeutics, Inc., Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14) (Attorney Morgan Chu added to party Juno Therapeutics, Inc.(pty:pla), Attorney Morgan Chu added to party Memorial Sloan Kettering Cancer Center(pty:pla), Attorney Morgan Chu added to party Sloan Kettering Institute for Cancer Research(pty:pla))(Chu, Morgan) (Entered: 10/18/2017)

Main Doc

3

Oct 18, 2017

Request for Clerk to Issue Summons on Complaint (Attorney Civil Case Opening),, 1 filed by Plaintiffs Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research. (Chu, Morgan) (Entered: 10/18/2017)

SKIPPED

46

Jan 29, 2018

JOINT REPORT Rule 26(f) Discovery Plan ; estimated length of trial 5-12 days, filed by Plaintiffs Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research.. (Attachments: # 1 Appendix 2)(Chu, Morgan) (Entered: 01/29/2018)

SKIPPED

66

Mar 29, 2018

AMENDED ANSWER and AMENDED COUNTERCLAIM to Complaint (Attorney Civil Case Opening),, 1 filed by Defendant and Counterclaimant Kite Pharma, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Appendix (redline version of amended pleading))(Lawton, Adam) (Entered: 03/29/2018)

SKIPPED

74

May 11, 2018

STIPULATION for Protective Order filed by Plaintiffs Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research. (Attachments: # 1 Proposed Order)(Tuan, Elizabeth) (Entered: 05/11/2018)

75

May 14, 2018

ORDER GRANTING PROTECTIVE ORDER by Magistrate Judge Rozella A. Oliver re Stipulation for Protective Order 74 (dml) (Entered: 05/14/2018)

Protective Order

SKIPPED

85

Aug 13, 2018

DECLARATION of Alan J. Heinrich re Brief (non-motion non-appeal), 84 ISO Juno’s Claim Construction Brief filed by Plaintiffs Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research, Counter Defendants Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research. (Attachments: # 1 Exhibit Exhibit 1, # 2 Exhibit Exhibit 2, # 3 Exhibit Exhibit 3, # 4 Exhibit Exhibit 4, # 5 Exhibit Exhibit 5, # 6 Exhibit Exhibit 6, # 7 Exhibit Exhibit 7, # 8 Exhibit Exhibit 8, # 9 Exhibit Exhibit 9, # 10 Exhibit Exhibit 10, # 11 Exhibit Exhibit 11)(Heinrich, Alan) (Entered: 08/13/2018)

Main Doc

Declaration

115

Dec 3, 2018

SEALED DECLARATION IN SUPPORT OF APPLICATION to file document (Reply in Support of Motion to Dismiss and Exhibits J-M) under seal 114 filed by Defendant Kite Pharma, Inc.. (Attachments: # 1 Unredacted Document Reply in Support of Motion to Dismiss, # 2 Unredacted Document Exhibit J, # 3 Unredacted Document Exhibit K, # 4 Unredacted Document Exhibit L, # 5 Unredacted Document Exhibit M)(Lawton, Adam) (Entered: 12/03/2018)

Main Doc

117

Jan 4, 2019

STIPULATION to AMEND Protective Order 75 filed by Defendant Kite Pharma, Inc.. (Attachments: # 1 Amended Protective Order, # 2 Proposed Order)(Lawton, Adam) (Entered: 01/04/2019)

118

Jan 7, 2019

ORDER GRANTING AMENDED PROTECTIVE ORDER by Magistrate Judge Rozella A. Oliver, re Stipulation to Amend Protective Order 117 (dml) (Entered: 01/07/2019)

119

Jan 7, 2019

AMENDED PROTECTIVE ORDER by Magistrate Judge Rozella A. Oliver, re Order Granting 118 (dml) (Entered: 01/07/2019)

122

Jan 24, 2019

Joint STIPULATION to Extend Discovery Cut-Off Date to March 29, 2019 filed by Plaintiffs Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research. (Attachments: # 1 Proposed Order)(Heinrich, Alan) (Entered: 01/24/2019)

Main Doc

SOURCE

https://www.courtlistener.com/docket/6175992/juno-therapeutics-inc-v-kite-pharma-inc/

Other related sources

35 U.S.C. 271 – Infringement of patent

Other related articles published in this Online Open Access Scientific Journal, include the following:

Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/10/04/economic-potential-of-a-drug-invention-prof-zelig-eshhar-weitzman-institute-registered-the-patent-versus-a-cancer-drug-in-clinical-trials-car-t-as-a-case-in-point-developed-by-kite-pharma-unde/

 

Read Full Post »


Newly Elect President of Technion, Professor Uri Sivan: Key Contributions to Scientific Innovations

 

Reporter: Aviva Lev-Ari, PhD, RN

 

February 7, 2019
By: Office of the Technion Spokesperson

The Technion Council, headed by Mr. Gideon Frank, has elected Professor Uri Sivan of the Faculty of Physics as the next president of Technion. The Council’s decision was based on the recommendation of the Search Committee for the Technion President and received sweeping support from the Academic Assembly. The appointment is subject to the final approval of the International Board of Governors, which is set to convene in June.

Professor Uri Sivan

Prof. Sivan will commence his term as President of Technion on October 1 2019, and will replace the outgoing President Prof. Peretz Lavie, who will complete his term after a decade in office.

Prof. Sivan, 64, a resident of Haifa, is married and the father of three. He served as a pilot in the Israeli Air Force. He has a BSc in Physics and Mathematics, an MSc and PhD in Physics, all with honors from Tel Aviv University.

In 1991, after three years at IBM’s T. J. Watson Research Center in New York, Prof. Sivan joined the Faculty of Physics at Technion.

SOURCE

https://ats.org/news/professor-uri-sivan-elected-new-president-of-the-technion/

 

Key Contributions to Scientific Innovations

  • His research has covered a wide range of fields including quantum mesoscopic physics and the harnessing of molecular and cellular biology for the self-assembly of miniature electronic devices. Prof. Sivan, along with colleagues Profs. Erez Braun and Yoav Eichen, demonstrated for the first time how to harness molecular recognition by DNA molecules for wiring an electric circuit. This study gained considerable resonance and helped pave the way for a new field in nanotechnology using the self-assembly properties of biological molecules to construct miniature engineering systems.
  • His research has focused on the way water orders next to molecules and the effect of this ordering on inter-molecular interactions in biologically relevant solutions. Within this framework, Prof. Sivan’s group designs and builds unique, ultra-high-resolution atomic force microscopes.
  • His research has led to patents and industrial applications. Recently, an Israeli start-up company was established in the field of single cell analysis for cancer diagnostics, based on the technology developed in Prof. Sivan’s lab.
  •  Prof. Sivan is the founding director of the Russell Berrie Nanotechnology Institute (RBNI), which he headed between 2005 and 2010.  RBNI has led the scientific revolution in nanotechnology at Technion and has placed the university at the forefront of global research in the field. RBNI made headlines when Prof. Sivan and Dr. Ohad Zohar engraved the entire Hebrew Bible onto a tiny silicon chip. The Nano Bible was written as part of an educational program developed by the Institute to increase young people’s interest in science and especially in nanotechnology. In 2009, President Shimon Peres presented the Nano Bible to Pope Benedict XVI during his official visit to Israel. Today, there are three copies of the chip worldwide: at the Vatican Library, the Smithsonian Museum in Washington D.C., and the Israel Museum in Jerusalem. The establishment of RBNI spearheaded the development of Israel’s national nanotechnology program, and together with centers established in other Israeli universities, has positioned the country as a world leader in nanotechnology.

APPOINTMENTS

Recently, Prof. Sivan was appointed to head the National Advisory Committee in Quantum Science and Technology of the Council for Higher Education’s Planning and Budgeting Committee (PBC). The committee outlined the national quantum academic program, which was adopted and launched last year.

Prof. Sivan has served as a member of the Israeli National Committee for Research and Development (MOLMOP) and the Scientific Advisory Committee of the Batsheva de Rothschild Foundation. He currently serves on the Advisory Committee of the Maof Fellowships Committee for advancing Arab faculty and is a member of the Israeli Wolfson Foundation Advisory Board.

AWARDS

Prof. Sivan is a renowned lecturer in Israel and abroad. He was awarded with numerous prizes including

  • the Mifal Hapais Landau Prize for the Sciences and Research,
  • the Rothschild Foundation Bruno Prize,
  • the Israel Academy of Sciences Bergmann Prize,
  • the Technion’s Hershel Rich Innovation Award, and
  • the Taub Award for Excellence in Research.

 

SOURCE

https://ats.org/news/professor-uri-sivan-elected-new-president-of-the-technion/

Read Full Post »

Older Posts »